- Investor's Business Daily•2 days ago
Axovant was unconcerned after rival Lundbeck failed a key hurdle in Phase 3 testing for its newest Alzheimer's treatment drug.
- Motley Fool•3 days ago
The launch of its Parkinson's disease psychosis drug is in its early stages, and key data from an Alzheimer's disease trial is on tap.
- Business Wire•5 days agoACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016, at 9:00 a.m.
ACADIA Pharmaceuticals Inc. (ACAD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||35.10 x 500|
|Ask||36.00 x 300|
|Day's Range||34.26 - 35.51|
|52wk Range||16.64 - 43.30|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-18.13|
|Avg Vol (3m)||1,888,331|
|Dividend & Yield||N/A (N/A)|